Navigation Links
Mayo Clinic researchers find tamoxifen's power comes from endoxifen
Date:12/11/2008

SAN ANTONIO - Mayo Clinic researchers have discovered that a chemical known as endoxifen appears to be the primary metabolite responsible for the effectiveness of tamoxifen in treating breast cancer, and that it works against cancer in an entirely unexpected way.

Their study, being presented at the Cancer Therapy & Research Center-American Association for Cancer Research (CTRC-AACR) 31st annual San Antonio Breast Cancer Symposium, finds that, in contrast to the other tamoxifen metabolites, endoxifen degrades the estrogen receptor, and inhibits the growth of breast cancer cells even when tamoxifen is present. These new findings are believed to be the most definite laboratory analysis yet on how tamoxifen and its two main metabolites - endoxifen and 4HT (4-hydroxytamoxifen) -act against breast cancer.

"Tens of thousands of women in this country are prescribed tamoxifen for either treatment or prevention of breast cancer, and while it has shown remarkable success, it does not work for a substantial number of patients," says the study's lead investigator, John Hawse, Ph.D. "These findings increase our understanding of tamoxifen and, we hope, could pave the way for improved therapies."

Tamoxifen is designed to treat estrogen-receptor positive breast cancer (70-80 percent of all breast cancer) because this receptor fuels the cancer's growth. But tamoxifen is a "pro-drug," which means that it is relatively inactive until converted into active "metabolites" - the 4HT and endoxifen chemicals that actually perform the work of the drug.

Researchers at Mayo Clinic earlier discovered that tamoxifen is less effective in women who had a deficiency in the enzyme CYP2D6, which is responsible for converting tamoxifen to endoxifen. The CYP2D6 gene is present in different forms in different people. A team of Mayo Clinic investigators, including Matthew Goetz, M.D., Matthew Ames, Ph.D., and James Ingle, M.D., have shown that women with certain variations in the CYP2D6 gene - so-called "poor metabolizers" - have a significantly higher risk of relapse when they take tamoxifen.

But it has been unclear which of tamoxifen's metabolites is most crucial to tamoxifen's effectiveness. Previous research suggested that both metabolites were similar.

To find the answer, Dr. Hawse, who works in the laboratory of molecular biologist Thomas Spelsberg, Ph.D., designed an in vitro model system for treating cancer cells with tamoxifen, 4HT, and endoxifen in amounts that mirrored doses found in women who were prescribed tamoxifen therapy.

The researchers were surprised to find that endoxifen actually degraded estrogen receptors in these cancer cells, thus slowing their growth.

"We all thought tamoxifen works by blocking the estrogen receptor so it can't bind to estrogen, but now we find that endoxifen actually degrades the estrogen receptor," Dr. Hawse says. "This goes a long way toward explaining why tamoxifen can be so effective in women who can effectively convert tamoxifen to endoxifen."

Dr. Hawse found that tamoxifen had little effect on the growth of the cancer cells. They also discovered that when they introduced into the cells a combination of estrogen and tamoxifen, the cells grew just as much as if they were given estrogen alone.

With endoxifen, the results were different. At low concentrations, such as would be seen in the blood of women who were poor metabolizers because of their CYP2D6 gene variant, there was little inhibition of cell growth. But at higher concentrations, similar to what good metabolizers produce, cancer growth drastically slowed and the estrogen receptor was degraded.

Adding the low concentrations of 4HT found in human blood to the cancer cells also had little effect, and cell growth also increased when estrogen was added. "This is not to say that 4HT is ineffective, but that the liver makes so little of it from tamoxifen that it can't work as well as it might if there was more of it," Dr. Hawse says.

"That was the evidence we needed," says Dr. Spelsberg. "It showed that tamoxifen is activated via the CYP2D6 enzyme into a completely different molecule that has a completely different mechanism of action from tamoxifen and even 4HT."

Based on these findings, the researchers say an agent that mimics endoxifen might be a better, more responsive drug than tamoxifen.

"These findings open the door to exploring the use of endoxifen as a drug that might be able to replace tamoxifen," says Dr. Goetz. "We believe it is the most potent metabolite, and we would not be restricted by CYP2D6's inability to metabolize it, or by limits on how much endoxifen the liver could make. It will take years before we know whether this is the case, but we are excited about the possibility."


'/>"/>

Contact: Karl Oestreich
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. New statement outlines essentials of heart failure clinics
2. Preferred Management Corp. Installs OpusClinicalSuite(R) at 2 Texas Hospitals
3. OptumHealth Launched myOptumHealth.com, Health and Wellness Information Destination with Clinically Reviewed Content, Tools and Resources
4. Advanced imaging technology used at Mayo Clinic improves spinal surgery outcome
5. Lifeclinic International and Get Real Consulting Team-Up to Launch Microsoft's HealthVault
6. December 2008 Mayo Clinic Womens HealthSource Highlights Happiness, Dementia and Smoking
7. December 2008 Mayo Clinic Health Letter Highlights: Colorectal Screenings, Lighting Tips for Low Vision and Generic Medications
8. Local Child Treated In Clinical Trial To Ease Symptoms of Cerebral Palsy
9. CVS/pharmacy and MinuteClinic Reach Goal of Delivering One Million Flu Vaccinations
10. Bio-Imaging Technologies Partners with AG Mednet to Offer Complete Imaging Solution for Clinical Trials : --Partnership Increases Trial Efficiency and Enhances Data Quality--
11. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... 2017 , ... The Cruise Web Inc. was recognized today as ... Annual MSC True Partnerships’ Awards. , The 2016 MSC True Partnerships Awards ... based on overall business growth in revenue and guests and continuous partnership support and ...
(Date:1/24/2017)... ... January 24, 2017 , ... West’s ... its annual Solutions Series of webinars will start January 31 with a session ... number of current health and benefits topics, including employee engagement, pricing transparency, population ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... Center ... 21st century leadership, has named Hector M. Chavez, Manager, Employee & Labor Relations at ... center - as its Hispanic Leader of the Month. City of Hope is committed ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... Really Need to Thrive , Well-meaning studies such as the Fordham Institute’s ... can better serve top students, such as including gifted or high-achieving students as ...
(Date:1/24/2017)... MA (PRWEB) , ... January 24, 2017 , ... American ... in Bedford, expanding access to high-quality health care for residents in the area. The ... fourth location opened during the past four years by Dave Adams and Dr. Kristina ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... Research and Markets has announced the addition of the ... - Forecast to 2025" report to their offering. ... The Global Implantable Medical ... 5.4% over the next decade to reach approximately $54.28 billion by ... is witnessing include 3D medical printing is expected to develop and ...
(Date:1/24/2017)... GAITHERSBURG, Md. , Jan. 24, 2017 /PRNewswire/ ... leader in the engineering and industrialization of biology to improve ... announced that it has entered into a definitive agreement to ... a clinical-stage company and pioneer in the development of AdenoVerse™ ... and expand upon GenVec,s expertise in adenoviral vectors and cGMP ...
(Date:1/24/2017)... 24, 2017   QR Pharma , Inc., ... novel therapies for the treatment of Alzheimer,s, Parkinson,s ... of four world-class key opinion leaders to its ... QR Pharma,s previous roster of impressive advisors in ... support the development of the breakthrough mechanism of ...
Breaking Medicine Technology: